Education
About Us
Working with TipRanks
Follow Us
Harmony Biosciences Holdings, Inc. (HRMY)
:HRMY
HRMY Stock Chart & Stats
$39.83
-$1.07(-3.04%)
At close: 4:00 PM EST
$39.83
-$1.07(-3.04%)
Day’s Range― - ―
52-Week Range$25.52 - $40.93
Previous CloseN/A
Volume87.33K
Average Volume (3M)827.92K
Market Cap
$2.29B
Enterprise Value$1.17B
Total Cash (Recent Filing)$672.58M
Total Debt (Recent Filing)$169.73M
Price to Earnings (P/E)12.5
Beta1.07
Next Earnings
Mar 03, 2026EPS Estimate
0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.87
Shares Outstanding57,596,360
10 Day Avg. Volume646,560
30 Day Avg. Volume827,921
Financial Highlights & Ratios
PEG Ratio0.75
Price to Book (P/B)2.97
Price to Sales (P/S)2.74
P/FCF Ratio8.95
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue1.42
Enterprise Value/Gross Profit1.83
Enterprise Value/Ebitda4.41
Forecast
1Y Price Target
$46.00Price Target Upside15.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPreliminary open-label extension data from the Phase 3 ARGUS trial showed an approximate 50% reduction in median countable motor seizures for patients with Dravet syndrome, with a favorable safety profile.
Earnings GrowthHarmony raised full-year 2025 revenue guidance to $845–$865 million, reflecting confidence in the underlying demand trajectory.
Pipeline DevelopmentThe positive results position Harmony on track for a potential new drug application (NDA) filing expected in early 2026, with a target PDUFA (FDA action) date in 1Q27.
Bears Say
Clinical Development RiskRisks include clinical development risk tied to pitolisant GR, pitolisant HD, and EPX100.
Market CompetitionConcerns exist that the epilepsy program lacks differentiation and the orexin program is entering a crowded market.
Pipeline SetbackThe Ph3 RECONNECT study missed its primary endpoint, leading to a major pipeline setback for Harmony Biosciences.
Harmony Biosciences Holdings News
HRMY FAQ
What was Harmony Biosciences Holdings, Inc.’s price range in the past 12 months?
Harmony Biosciences Holdings, Inc. lowest stock price was $25.52 and its highest was $40.93 in the past 12 months.
What is Harmony Biosciences Holdings, Inc.’s market cap?
Harmony Biosciences Holdings, Inc.’s market cap is $2.29B.
When is Harmony Biosciences Holdings, Inc.’s upcoming earnings report date?
Harmony Biosciences Holdings, Inc.’s upcoming earnings report date is Mar 03, 2026 which is in 84 days.
How were Harmony Biosciences Holdings, Inc.’s earnings last quarter?
Harmony Biosciences Holdings, Inc. released its earnings results on Nov 04, 2025. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.811 by $0.059.
Is Harmony Biosciences Holdings, Inc. overvalued?
According to Wall Street analysts Harmony Biosciences Holdings, Inc.’s price is currently Undervalued.
Does Harmony Biosciences Holdings, Inc. pay dividends?
Harmony Biosciences Holdings, Inc. does not currently pay dividends.
What is Harmony Biosciences Holdings, Inc.’s EPS estimate?
Harmony Biosciences Holdings, Inc.’s EPS estimate is 0.85.
How many shares outstanding does Harmony Biosciences Holdings, Inc. have?
Harmony Biosciences Holdings, Inc. has 57,596,360 shares outstanding.
What happened to Harmony Biosciences Holdings, Inc.’s price movement after its last earnings report?
Harmony Biosciences Holdings, Inc. reported an EPS of $0.87 in its last earnings report, beating expectations of $0.811. Following the earnings report the stock price went up 4.739%.
Which hedge fund is a major shareholder of Harmony Biosciences Holdings, Inc.?
Currently, no hedge funds are holding shares in HRMY
Harmony Biosciences Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$46.00 (15.49% Upside)
$46.00 (15.49% Upside)
Blogger Sentiment
Bullish
HRMY Sentiment 70%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 147.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.8%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.93%
12-Months-Change
Fundamentals
Return on Equity
25.93%
Trailing 12-Months
Asset Growth
30.18%
Trailing 12-Months
Company Description
Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with neurological disorders. The company primarily operates in the healthcare sector, specializing in treatments for conditions such as narcolepsy and other sleep disorders. Harmony's core products include its proprietary medications designed to improve the quality of life for patients suffering from these debilitating conditions.
HRMY Company Deck
HRMY Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance in revenue growth and patient adds, showcasing the company's robust cash position and promising pipeline advancements. However, challenges were noted in the Fragile X syndrome study and increased operating expenses.View all HRMY earnings summariesHRMY Stock 12 Month Forecast
Average Price Target
$46.00
▲(15.49% Upside)
Technical Analysis
Ownership Overview
1.04% Insiders
21.35% Mutual Funds
15.42% Other Institutional Investors
35.96% Public Companies and Individual Investors